Navigation Links
TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today promising results of its phase I clinical trials demonstrating the safety and pharmacokinetic profile of its ViaDerm-hPTH (1-34) product for the treatment of osteoporosis.

A seven day, repeated dose application, parallel group study was conducted on 48 healthy, elderly, post-menopausal women. The study was designed to evaluate the safety and tolerability of ascending multiple doses of hPTH (1-34) patches and to compare the pharmacokinetic profiles of the transdermally delivered doses of hPTH (1-34) with that of FORTEO(R) administered subcutaneously.

Transdermal hPTH (1-34) was delivered using TransPharma's fully integrated product, which is comprised of a proprietary pocket-sized device and 1 cm(2) dry hPTH (1-34) patch with demonstrated room-temperature stability.

Once-daily transdermal delivery of all doses tested in this trial demonstrated a safety profile similar to the one observed in the FORTEO(R) subcutaneous injection. All safety parameters (including calcium and phosphorous) of the different transdermal doses were within the normal range. Furthermore, all ViaDerm-hPTH (1-34) doses were very well tolerated by participants.

Pharmacokinetic profiles of hPTH (1-34) in the first and seventh day were similar, showing no accumulation of hPTH (1-34) levels and no deterioration in hPTH (1-34) systemic levels. These findings demonstrate the ViaDerm-hPTH (1-34) product's ability to provide reproducible drug levels resulting in excellent inter- and intra-participant variability.

Transdermally delivered hPTH (1-34) of all doses showed desirable peak profiles with relative bioavailability of approximately 40%. This bioavailability is amo
'"/>




Page: 1 2 3

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
7. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
8. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
9. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
10. Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
(Date:5/21/2013)... May 21, 2013 Hurel Corporation ("Hurel"), a ... cell-based assay platforms, today announced the appointment of ... the Company,s Board of Directors. Dr. MacDonald is the ... Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical development ... Merck & Co. in 2009. Over a ...
(Date:5/21/2013)... BioElectronics Corp. (PINKSHEETS: BIEL), the maker ... that CEO, Andrew J. Whelan ... Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments ... counter sales. "It,s been 37 years ... schema," Whelan said.  "While the old classification of ...
(Date:5/21/2013)...   Accuray Incorporated (Nasdaq: ... results involving hundreds of prostate cancer patients treated ... widely used form of prostate stereotactic body radiation ... a median of 5 years, and many to ... of patients with low-risk and 90.7% of patients ...
Breaking Medicine Technology:Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3
(Date:5/21/2013)... LEAWOOD, Kan. Primary care practice transformation on ... health care reform efforts aimed at achieving better ... Amid emerging evidence that transformation toward the patient-centered ... today,s health care environment, the U.S. Department of ... and Quality funded 14 studies to learn more ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Mecklenburg EMS ... will hold a free Community Wellness Fair to educate ... The fair will be held on Wednesday, May 22, 2013 ... City YMCA (8100 Old Mallard Creek Road, Charlotte, NC ... Heart Association and the Mecklenburg County Department of ...
(Date:5/21/2013)... Orsiro stent, which is a novel stent platform ... to the Xience Prime everolimus-eluting stent for the ... at nine months in the results of an ... The BIOFLOW-II substudy used intravascular ultrasound (IVUS) and ... hyperplasia and stent apposition at nine months after ...
(Date:5/21/2013)... Boca Raton, Fla. (PRWEB) May 21, 2013 ... TV program distributed on cable networks and cable channels ... of new episodes on its YouTube channel. The producers ... profiles of companies in the shipping industry, the manufacturing ... program highlights pioneering medical facilities and medical practitioners in ...
(Date:5/21/2013)... 21, 2013 MedMar Healing Center ... benefit Second Harvest Food Bank. Twenty-eight businesses, including MedMar Healing ... the food drive. The goal is to raise food to ... problems facing their families in recent years. , “We ... help those in need,” explains Douglas Chloupek of MedMar Healing ...
Breaking Medicine News(10 mins):Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2
... Covance Inc. (NYSE: CVD ) today announced that ... on Wednesday, March 11, 2009 at 1:30 p.m. (ET). ... www.covance.com . In order to register and download ... headquarters in Princeton, New Jersey, is one of the world,s ...
... California, San Diego School of Medicine have identified a key ... to divide and replicate themselves. The rapid generation of ... body,s antibody defense mechanism. However, when B cells grow ... multiple myeloma or, when they grow to attack the wrong ...
... Selects Desktop and Production Messaging Solutions for Significant Savings, ... ... Norcross, GA (PRWEB) March 8, ... (NasdaqCM: ESIC)(easylink.com), a global provider of comprehensive messaging services, ...
... Jacqueline Foreman is pleased to be interviewing Dr. Barry Sears ... Talk Radio on Blogtalkradio at www.blogtalkradio.com/yourmentalhealth on Tuesday, ... Listeners are encouraged to call in with their questions at ... join our live members only chat session. If you miss ...
... as family situations change, study finds , , SATURDAY, March ... spoiling grandchildren, but a new study says they might ... and behavior. , Spending time with grandma ... divorced/separated or stepfamily households, according to the report, published ...
... Church of Scientology,s Freedom Magazine article on psychiatric screening was ... , ... Los Angeles, Ca (PRWEB) March 6, 2009 ... has been recognized by the Religion Communicators Council (RCC) with the ...
Cached Medicine News:Health News:Protein helps immune cells to divide and conquer 2Health News:Email Fax Provider, EasyLink Services, Announces Prominent Bio-Pharma Signing 2Health News:Email Fax Provider, EasyLink Services, Announces Prominent Bio-Pharma Signing 3Health News:Zone Diet Creator Dr. Barry Sears to Talk About Latest Book Toxic Fat: When Good Fat Turns Bad 2Health News:Zone Diet Creator Dr. Barry Sears to Talk About Latest Book Toxic Fat: When Good Fat Turns Bad 3Health News:In Tough Times, Kids May Find Solace With Grandparents 2Health News:Scientology Magazine Earns Religion Communicators Council Award 2
... Synergy T-EP - EMG/EP monitoring systems range ... T2EP, T5EP and T10EP systems. These 2, ... in collaboration with leading practitioners, for ease ... of clinical testing. Synergy T-EP harnesses PC ...
Neuropack Sigma MEB-5500 series evoked potential measuring system is a compact, portable, all-in-one unit....
... MYOHANDY family are probably the most ... SystemPLUS line. Based on last generation ... the ISA 100x EP series with ... EP) , 4 channels (ISA 1004, ...
Sierra II power & efficiency plus. Sierra II report generator with automatic sentence generation creates the one-minute report. Complete 2/4 channel EMG/NCV/EP....
Medicine Products: